Dupuytren’s Disease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Diagnosis (Physical Examination, X-ray), Treatment (Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others)), By Disease Type (Type I, Type II, Type III), By End-use (Hospitals, Clinics, Academic & Research Institute, Others), By Region, Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

USD 4.23 billion

CAGR (2023-2028)

4.31%

Fastest Growing Segment

Treatment

Largest Market

Europe


Market Overview

Global Dupuytren’s Disease Market has valued at USD 4.23 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 4.31% through 2028. Dupuytren's disease, also known as Dupuytren's contracture, is a progressive condition that affects the connective tissue beneath the skin of the palm and fingers. Named after the French surgeon Baron Guillaume Dupuytren who first described it in the 19th century, this condition primarily causes the fingers to bend towards the palm, leading to functional limitations. Despite extensive research, the precise cause of Dupuytren's disease remains uncertain. Genetic predisposition is widely recognized as a significant factor. Individuals with a family history of the disease are at a higher risk of developing it themselves. Certain ethnic backgrounds, including Northern European and Scandinavian populations, also have an increased prevalence of the condition. Other risk factors include age, gender (men are more susceptible), smoking, and alcohol consumption. The characteristic of Dupuytren's disease is the formation of thickened tissue beneath the skin in the palm and fingers. This tissue, known as palmar fascia, gradually contracts over time, causing the fingers to bend inward. Early symptoms may include the appearance of small nodules or lumps in the palm. As the disease progresses, these nodules can merge and form cords, leading to finger contractures. The condition typically affects the ring and little fingers, but it can involve other fingers as well. These contractures can result in reduced finger extension, making everyday tasks such as grasping objects or shaking hands challenging. Additionally, Diagnosing Dupuytren's disease is often based on a physical examination of the hands and fingers. Doctors look for the presence of nodules or cords beneath the skin and assess the degree of finger contractures. In some cases, imaging tests such as ultrasound or MRI might be used to visualize the extent of tissue involvement. Early diagnosis is crucial for better management and treatment outcomes. Furthermore, treatment for Dupuytren's disease depends on the severity of the contractures and the impact on the patient's daily life. Mild cases might not require intervention beyond regular monitoring.

 Key Market Drivers

Rising Prevalence and Awareness

The prevalence of Dupuytren's disease has shown a consistent uptick over the years. This condition predominantly affects individuals of Northern European descent, with a higher incidence observed in men and those over the age of 50. As the global population ages and awareness about this condition increases, more patients are seeking medical attention. This growing patient pool is a significant driver of market growth, as it generates demand for both diagnosis and treatment options. As the prevalence of Dupuytren's disease continues to rise, so does the awareness surrounding this often-overlooked ailment. In the past, many individuals who exhibited early symptoms or mild contractures may not have sought medical attention, attributing their discomfort to age or other minor causes. However, a shift in public and medical awareness has paved the way for earlier diagnosis and intervention. Efforts to raise awareness are multifaceted. Healthcare providers are becoming more attuned to the signs of Dupuytren's disease and are actively engaging patients in discussions about symptoms and risk factors. As a result, individuals experiencing hand discomfort, nodules, or contractures are more likely to seek medical evaluation, leading to timely diagnosis and intervention. Patient advocacy groups and medical organizations have also played a pivotal role in disseminating information about Dupuytren's disease. Through online resources, support networks, and awareness campaigns, these entities have helped individuals recognize the condition's symptoms, understand its impact on daily life, and connect with medical professionals specializing in its treatment. Moreover, heightened awareness among patients and healthcare providers has led to earlier diagnosis and intervention. In the past, the slow progression of the disease often meant that patients sought treatment only when their hand function was severely compromised. Now, with improved understanding and awareness, patients are seeking medical help at earlier stages, leading to a higher demand for a range of treatment modalities.

Advancements in Treatment Options

In the field of medicine, progress is often marked by the development of innovative treatment approaches. Dupuytren's disease has not been an exception. Traditionally, surgical procedures were the mainstay for severe cases, involving the excision of the abnormal tissue causing the finger contractures. However, as medical science has evolved, a plethora of non-surgical and minimally invasive treatments have emerged, providing patients with a wider array of choices. Enzyme-based treatments, such as collagenase injections, have gained popularity as a less invasive alternative. These injections help break down the collagen that forms the cords, allowing for easier manipulation of the fingers and potentially delaying or obviating the need for surgery. Similarly, needle aponeurotomy has gained traction as a minimally invasive procedure that involves using a needle to puncture and release the cords, restoring finger mobility. The development of targeted drug therapies is also a promising avenue. Researchers are exploring medications that can modify the underlying processes that lead to Dupuytren's disease, potentially halting its progression or preventing its recurrence after treatment. Among the pioneering advancements in Dupuytren's disease treatment are enzyme-based interventions, notably collagenase injections. Collagenase is an enzyme that targets the collagen that forms the cords beneath the skin. Injected directly into the contracted tissue, collagenase weakens the collagen, allowing for easier manual manipulation to straighten the finger. This minimally invasive approach has transformed the landscape of Dupuytren's disease treatment by providing an alternative to surgery. Patients are drawn to the prospect of avoiding surgery, with its associated risks and recovery time, while still achieving improved hand function. Additionally, Another revolutionary technique that has gained traction is needle aponeurotomy. This minimally invasive procedure involves using a needle to puncture and break the cords, enabling the fingers to be extended. This approach has the advantage of quicker recovery times compared to traditional surgery, making it an attractive option for patients seeking expedited rehabilitation. Moreover, needle aponeurotomy can be performed on an outpatient basis, reducing the need for lengthy hospital stays and associated costs.

Research and Collaboration

The collaborative efforts between medical researchers, pharmaceutical companies, and healthcare institutions are playing a pivotal role in driving the Dupuytren's disease market forward. Increased research funding and initiatives have allowed for a deeper understanding of the disease's genetic and molecular underpinnings. This, in turn, has opened avenues for the development of more precise and effective treatment strategies. Research into the genetic basis of Dupuytren's disease has led to the exploration of gene therapies. Techniques such as gene editing hold immense promise in altering the genetic factors contributing to the condition, potentially offering long-term solutions for patients. Researchers are delving into the genetic and molecular mechanisms that underlie Dupuytren's disease, with the aim of developing interventions that address the root causes. These targeted therapies hold the promise of not only mitigating the symptoms but potentially halting or slowing the progression of the disease. This frontier of research aligns with the growing emphasis on precision medicine, tailoring treatments to the specific genetic and molecular profiles of individual patients. Also, through a combination of genetic studies, molecular analysis, and clinical investigations, researchers have made significant strides in deciphering the genetic predisposition and underlying biological processes that lead to Dupuytren's disease. This knowledge forms the foundation for the development of targeted therapies that could potentially halt the disease's progression or prevent its recurrence after treatment. The dynamic landscape of Dupuytren's disease research thrives on collaboration. Researchers, medical professionals, surgeons, geneticists, and pharmacologists collaborate to pool their expertise and insights, contributing to a more comprehensive understanding of the condition. This interdisciplinary approach fosters a rich exchange of ideas and accelerates the pace of discovery. Moreover, collaboration extends beyond the boundaries of academia and research institutions. Pharmaceutical companies, medical device manufacturers, and biotechnology firms also play a pivotal role. These entities collaborate with researchers to translate scientific findings into practical interventions, be it innovative treatments, diagnostic tools, or rehabilitative technologies. Such collaborations bridge the gap between research discoveries and tangible solutions that can benefit patients. Patient advocacy also empowers individuals to actively engage in their healthcare journey. Informed patients are better equipped to make decisions about their treatment options, participate in clinical trials, and contribute to research efforts. This participatory approach not only benefits individual patients but also enriches the collective knowledge base surrounding Dupuytren's disease.

 

Download Free Sample Report

Key Market Challenges

Limited Awareness and Diagnosis

Despite the increasing prevalence of Dupuytren's disease, limited awareness remains a significant challenge. Many individuals, especially in the early stages of the condition, may mistake the symptoms for normal signs of aging or other minor discomforts. As a result, diagnosis is often delayed, impeding timely intervention. Healthcare providers play a pivotal role in enhancing awareness and facilitating early diagnosis. However, due to the rarity of the condition and a lack of standardized diagnostic criteria, healthcare professionals might not always be attuned to recognizing Dupuytren's disease. Overcoming this challenge necessitates comprehensive educational initiatives that target both medical practitioners and the general public, increasing awareness about the symptoms, risk factors, and available treatments.

Access to Specialized Care

The demand for Dupuytren's disease treatments places a spotlight on the need for specialized medical care. Surgeons, physiotherapists, and hand therapists with expertise in treating the condition are essential for providing optimal patient outcomes. However, access to specialized care can be limited in certain regions, especially in rural or underserved areas.

This challenge is compounded by the fact that Dupuytren's disease is often underdiagnosed or misdiagnosed, leading to delayed referrals to specialists. Addressing this issue requires efforts to establish referral pathways and enhance collaboration between general practitioners and specialists. Telemedicine and telehealth initiatives could also bridge the gap by connecting patients with experts remotely.

Treatment Costs and Reimbursement

The economic burden of Dupuytren's disease treatment can be substantial, presenting a barrier to patient access. While non-surgical treatments like enzyme-based interventions may seem attractive, they can come with high costs, especially when factoring in the need for multiple injections. Surgical procedures, while effective, might also entail significant expenses related to hospital stays, surgeon fees, and post-operative rehabilitation. Navigating the complexities of insurance coverage and reimbursement is another challenge. Some treatment options might not be covered by insurance plans, leaving patients to shoulder the financial burden. Addressing this challenge requires collaboration between healthcare providers, insurance companies, and policymakers to ensure that effective treatments are accessible to a broader patient population.

Key Market Trends

Patient-Centric Healthcare Approach

A paradigm shift toward patient-centric healthcare is sweeping through the medical field. Patients are no longer passive recipients of care but active participants in their treatment journeys. This shift is particularly relevant to conditions like Dupuytren's disease, where treatment choices can impact patients' quality of life. As patients become more informed and empowered, they demand treatment options that align with their preferences, lifestyles, and goals. This demand for personalized care is driving the development of a diverse range of treatment modalities to cater to varying patient needs.

Advancements in Minimally Invasive Techniques

The rise of minimally invasive medical techniques is a game-changer in the Dupuytren's disease market. Traditional surgical procedures often involved prolonged hospital stays, significant scarring, and extended recovery times. The advent of minimally invasive approaches, such as enzyme-based treatments and needle aponeurotomy, is revolutionizing patient care. These techniques offer quicker recovery times, reduced scarring, and often allow patients to return to their daily activities sooner. As a result, patients are increasingly drawn to these less invasive options, thus boosting their demand within the market.

Research into Targeted Therapies

Advancements in medical research have paved the way for targeted therapies in various medical fields, and Dupuytren's disease is no exception. Researchers are delving into the genetic and molecular mechanisms underlying the condition, aiming to develop treatments that address its root causes. The potential for targeted therapies that halt or slow down the progression of Dupuytren's disease is garnering significant attention. As these treatments become more refined, they are expected to drive demand by offering patients innovative options that go beyond symptom management.

Segmental Insights

Disease Type Insights

In 2022, the Dupuytren’s Disease Market was dominated by the disease type II segment and accounted for largest share in the market.  The dominant market segment is anticipated to be Type II Dupuytren's, which is characterised by involvement of the palmar fascia and digital cords resulting in finger flexion abnormalities. Recent thorough study on the disease's prevalence around the world shows that type II accounts for a sizable share of diagnosed cases, highlighting its higher prevalence and effect.

Type Insights

In 2022, the Dupuytren’s Disease Market was dominated by the treatment segment and is predicted to continue expanding over the coming years. The dominance is anticipated to the increased attention being paid to creating powerful therapeutic choices for controlling the illness and enhancing patients' wellbeing. Pharmaceutical firms and makers of medical equipment have been working hard to introduce cutting-edge treatment modalities through research and development initiatives.

 

Download Free Sample Report

Regional Insights

The Europe region has established itself as the leader in the Global Dupuytren’s Disease Market and it is anticipated that it will continue to do so throughout the forecast period. This can be accredited to several factors such as the increased disease prevalence, established healthcare systems with cutting-edge infrastructure, and vigorous research & development programmes.

Recent Developments

  • Recent research has illuminated the genetic underpinnings of Dupuytren’s disease, offering insights into the condition’s inheritance patterns and potential targets for therapy. Genetic studies have identified specific genes associated with Dupuytren’s disease susceptibility, shedding light on the molecular mechanisms driving the condition.
  • Collagenase injections offer patients the advantage of reduced scarring, quicker recovery times, and the potential to regain hand function without undergoing extensive surgery. Market leaders in this space have played a pivotal role in conducting clinical trials, obtaining regulatory approvals, and bringing this novel treatment option to the forefront of Dupuytren's disease management.

Key Market Players

  • Novartis AG
  • Pfizer Inc.
  • Bayer AG
  • Nantong Jinghua Pharmaceutical Co., Ltd
  • Actiza Pharmaceutical Private Limited
  • Endo International plc
  • Spear Pharmaceuticals
  • Hikma Pharmaceuticals PLC
  • Bristol-Myers Squibb
  • Glaxosmithkline PLC.

 By Type

 By Disease Type

By End User

By Region
  • Diagnosis
  • Treatment
  • Type I
  • Type II
  • Type III

 
  • Hospitals
  • Clinics
  • Academic & Research Institute
  • Others
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

 

 

Report Scope:

In this report, the Global Dupuytren’s Disease Market   has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Dupuytren’s Disease Market, By Type:

o   Diagnosis {Physical Examination, X-ray}

o   Treatment {Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others}

  • Dupuytren’s Disease Market, By Disease Type:

o   Type I

o   Type II

o   Type III

  • Dupuytren’s Disease Market, By End-use:

o   Hospitals

o   Clinics

o   Academic & Research Institute

o   Others

  • Global Dupuytren’s Disease Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dupuytren’s Disease Market.

Available Customizations:

Global Dupuytren’s Disease Market   report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Dupuytren’s Disease Market   is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Dupuytren’s Disease Market Outlook

5.1.  Market Size & Forecast

5.1.1.    By Value

5.1.2.    Market Share & Forecast

5.1.3.    By Type (Diagnosis (Physical Examination, X-ray), Treatment (Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others))

5.1.4.    By Disease Type (Type I, Type II, Type III)

5.1.5.    By End-use (Hospitals, Clinics, Academic & Research Institute, Others)

5.1.6.    By Company (2022)

5.1.7.    By Region

5.2.  Market Map

6.    North America Dupuytren’s Disease Market Outlook

6.1.  Market Size & Forecast

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Type

6.2.2.    By Disease Type

6.2.3.    By End-use

6.2.4.    By Country

6.3.  North America: Country Analysis

6.3.1.    United States Dupuytren’s Disease Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.            By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.            By Type

6.3.1.2.2.            By Disease Type

6.3.1.2.3.            By End-Use

6.3.2.    Mexico Dupuytren’s Disease Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.            By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.            By Type

6.3.2.2.2.            By Disease Type

6.3.2.2.3.            By End-Use

6.3.3.    Canada Dupuytren’s Disease Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.            By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.            By Type

6.3.3.2.2.            By Disease Type

6.3.3.2.3.            By End-Use

7.    Europe Dupuytren’s Disease Market Outlook

7.1.  Market Size & Forecast

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Type

7.2.2.    By Disease Type

7.2.3.    By End-use

7.2.4.    By Country

7.3.  Europe: Country Analysis

7.3.1.    France Dupuytren’s Disease Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.            By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.            By Type

7.3.1.2.2.            By Disease Type

7.3.1.2.3.            By End-Use

7.3.2.    Germany Dupuytren’s Disease Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.            By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.            By Type

7.3.2.2.2.            By Disease Type

7.3.2.2.3.            By End-Use

7.3.3.    United Kingdom Dupuytren’s Disease Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.            By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.            By Type

7.3.3.2.2.            By Disease Type

7.3.3.2.3.            By End-Use

7.3.4.    Italy Dupuytren’s Disease Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.            By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.            By Type

7.3.4.2.2.            By Disease Type

7.3.4.2.3.            By End-Use

7.3.5.    Spain Dupuytren’s Disease Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.            By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.            By Type

7.3.5.2.2.            By Disease Type

7.3.5.2.3.            By End-Use

8.    Asia-Pacific Dupuytren’s Disease Market Outlook

8.1.  Market Size & Forecast

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Type

8.2.2.    By Disease Type

8.2.3.    By End-use

8.2.4.    By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.    China Dupuytren’s Disease Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.            By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.            By Type

8.3.1.2.2.            By Disease Type

8.3.1.2.3.            By End-Use

8.3.2.    India Dupuytren’s Disease Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.            By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.            By Type

8.3.2.2.2.            By Disease Type

8.3.2.2.3.            By End-Use

8.3.3.    South Korea Dupuytren’s Disease Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.            By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.            By Type

8.3.3.2.2.            By Disease Type

8.3.3.2.3.            By End-Use

8.3.4.    Japan Dupuytren’s Disease Market Outlook

8.3.4.1.        Market Size & Forecast

8.3.4.1.1.            By Value

8.3.4.2.        Market Share & Forecast

8.3.4.2.1.            By Type

8.3.4.2.2.            By Disease Type

8.3.4.2.3.            By End-Use

8.3.5.    Australia Dupuytren’s Disease Market Outlook

8.3.5.1.        Market Size & Forecast

8.3.5.1.1.            By Value

8.3.5.2.        Market Share & Forecast

8.3.5.2.1.            By Type

8.3.5.2.2.            By Disease Type

8.3.5.2.3.            By End-Use

9.    South America Dupuytren’s Disease Market Outlook

9.1.  Market Size & Forecast

9.1.1.    By Value

9.2.  Market Share & Forecast

9.2.1.    By Type

9.2.2.    By Disease Type

9.2.3.    By End-use

9.2.4.    By Country

9.3.  South America: Country Analysis

9.3.1.    Brazil Dupuytren’s Disease Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.            By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.            By Type

9.3.1.2.2.            By Disease Type

9.3.1.2.3.            By End-Use

9.3.2.    Argentina Dupuytren’s Disease Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.            By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.            By Type

9.3.2.2.2.            By Disease Type

9.3.2.2.3.            By End-Use

9.3.3.    Colombia Dupuytren’s Disease Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.            By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.            By Type

9.3.3.2.2.            By Disease Type

9.3.3.2.3.            By End-Use

10.  Middle East and Africa Dupuytren’s Disease Market Outlook

10.1.   Market Size & Forecast         

10.1.1. By Value

10.2.   Market Share & Forecast

10.2.1. By Type

10.2.2. By Disease Type

10.2.3. By End-use

10.2.4. By Country

10.3.   MEA: Country Analysis

10.3.1. South Africa Dupuytren’s Disease Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Type

10.3.1.2.2.         By Disease Type

10.3.1.2.3.         By End-Use

10.3.2. Saudi Arabia Dupuytren’s Disease Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Type

10.3.2.2.2.         By Disease Type

10.3.2.2.3.         By End-Use

10.3.3. UAE Dupuytren’s Disease Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Type

10.3.3.2.2.         By Disease Type

10.3.3.2.3.         By End-Use

11.  Market Dynamics

11.1.   Drivers

11.2.   Challenges

12.  Market Trends & Developments

12.1.   Recent Developments

12.2.   Product Launches

12.3.   Mergers & Acquisitions

13.  PESTLE Analysis

14.  Porter’s Five Forces Analysis

14.1.   Competition in the Industry

14.2.   Potential of New Entrants

14.3.   Power of Suppliers

14.4.   Power of Customers

14.5.   Threat of Substitute Product

15.  Competitive Landscape

15.1.   Business Overview

15.2.   Company Snapshot

15.3.   Products & Services

15.4.   Financials (In case of listed companies)

15.5.   Recent Developments

15.6.   SWOT Analysis

15.6.1. Novartis AG

15.6.2. Pfizer Inc.

15.6.3. Bayer AG

15.6.4. Nantong Jinghua Pharmaceutical Co., Ltd

15.6.5. Actiza Pharmaceutical Private Limited

15.6.6. Endo International plc

15.6.7. Spear Pharmaceuticals

15.6.8. Hikma Pharmaceuticals PLC

15.6.9. Bristol-Myers Squibb

15.6.10.               GlaxoSmithKline Plc.

16. Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Dupuytren’s Disease Market was estimated to be USD 4.23 billion in 2022.

down-arrow

Novartis AG, Pfizer Inc., Bayer AG, Nantong Jinghua Pharmaceutical Co., Ltd, Actiza Pharmaceutical Private Limited, Endo International plc, Spear Pharmaceuticals, Hikma Pharmaceuticals PLC, Bristol-Myers Squibb, Glaxosmithkline PLC., etc. are some of the key players operating in the Global Dupuytren’s Disease Market.

down-arrow

The need for early diagnosis methods and high price for treatments are the major challenges faced by the Global Dupuytren’s Disease Market in the upcoming years.

down-arrow

Increasing prevalence of the Dupuytren’s disease and growing awareness among patients and healthcare providers, are majorly driving the demand for the global Dupuytren’s Disease Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Dupuytren’s Disease Market to Grow with a CAGR of 4.31% through 2028

Oct, 2023

The growing shift towards personalized medicine and rising awareness of Dupuytren’s Disease are the major drivers for the Global Dupuytren’s Disease Market.

Why Choose Us